PDZD8

Across TCGA pan-cancer cohorts, PDZD8 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PDZD8 data layer compared with 26 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PDZD8 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PDZD8 expression acts as an unfavorable survival marker, although some lineages such as PDAC and UCEC show a favorable association.

LUAD, PDAC, and HNSC are the cancer types where PDZD8 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	II,III,IV	0.320	0.777	<.001	41	view →
PDAC	OS	Median	III,IV	0.601	0.272	.004	15	view →
HNSC	DFS	Median	II,III,IV	0.682	0.871	.023	5	view →
UCEC	OS	Tertile	All	1.000	0.931	.043	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PDZD8–LUAD (DFS)

Open the LUAD breakdown →